Calciphylaxis (calcific uremic arteriolopathy) is a rare, potentially life-threatening condition in which vascular calcification produces ulcerative skin lesions. Calciphylaxis was first described in patients with end-stage renal disease receiving dialysis, with an annual incidence of 35 cases per 10 000 patients in the United States.1 Calciphylaxis has also been observed in patients without renal disease, and the condition is termed nonuremic calciphylaxis (NUC). The most common underlying conditions associated with NUC are hyperparathyroidism, malignant neoplasm, alcoholic liver disease, and autoimmune disorders.2 In addition, exposure to some medications, such as corticosteroids, may increase the risk of NUC, possibly by affecting the receptor activator of nuclear factor-κB, receptor activator of nuclear factor-κB ligand, or osteoprotegerin, which are involved in regulation of extraskeletal calcification.3 With this knowledge, we sought to investigate the demographics, comorbid conditions, and outcomes of patients with NUC at the University of Washington hospitals and to compare this information with prior published findings.
Altman K, Shinohara M. Demographics, Comorbid Conditions, and Outcomes of Patients With Nonuremic Calciphylaxis. JAMA Dermatol. Published online January 02, 2019. doi:10.1001/jamadermatol.2018.4937
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: